Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication NEURACEQ is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products NEURACEQ is a radioactive… FDA label
Florbetaben F18 · 1 trial · 1 indication
Percent Test-Retest variability (%) of cardiac 18F florbetaben PET
| Arm | Type | Description |
|---|---|---|
| Patients with cardiac disease | EXPERIMENTAL | All eligible AL, ATTR and non-CA patients will receive two injections of the investigational imaging agent florbetaben: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 patients of each group will be required. |
| Name | Type | Description |
|---|---|---|
| Florbetaben F18 | DRUG | Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq). |
Inclusion Criteria: * Inclusion criteria (for all subjects): * Males and females aged ≥40 years * Able to understand, sign, and date written informed consent * Written informed consent must be obtained before any assessment is performed * Female subjects must be documented by medical recor...
Top 5 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc | ALNY | 5 | PHASE3 | Vutrisiran, Nucresiran, patisiran |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Coramitug |
| AstraZeneca PLC | AZN | 4 | PHASE3 | Eplontersen, ALXN2220 |
| Intellia Therapeutics, Inc. | NTLA | 2 | PHASE3 | Nexiguran ziclumeran |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Eplontersen |
Florbetaben F18 is an investigational small molecule being studied for use in Cardiac Amyloidosis, a condition where abnormal protein deposits accumulate in the heart. It is a radioactive diagnostic agent that binds to beta-amyloid deposits, potentially allowing visualization of cardiac amyloidosis through imaging. The drug is currently in Phase 1 clinical development.
Florbetaben F18 targets beta-amyloid, a protein that forms abnormal deposits in tissues. In Cardiac Amyloidosis, these deposits can accumulate in the heart muscle. By binding to beta-amyloid, Florbetaben F18 may enable detection of amyloid deposits through positron emission tomography (PET) imaging, helping to diagnose or monitor the condition.
Florbetaben F18 is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH. The company is conducting clinical research to evaluate the drug's potential as a diagnostic imaging agent for Cardiac Amyloidosis.
Florbetaben F18 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug's properties in patients with Cardiac Amyloidosis.
Florbetaben F18 is being studied in a Phase 1 clinical trial with the identifier NCT06790394, titled "Test-retest Study With [18F]FBB in Cardiac Amyloidosis." This single-center study in the United Kingdom is recruiting 15 participants aged 40 years and older with Cardiac Amyloidosis. The trial is uncontrolled and not randomized or blinded.